Percutaneous pulmonary valve implantation

نویسندگان

Hussam S. Suradi

Ziyad M. Hijazi

چکیده

INTRODUCTION Percutaneous pulmonary valve implantation (PPVI) is one of the most exciting recent developments in the treatment of structural heart disease and has evolved as an attractive alternative to surgery in patients with dysfunctional right ventricle-pulmonary artery conduits. Although surgical pulmonary valve replacement is associated with low morbidity and mortality rates, there are many instances when operative risks are high or surgery is prohibitive. Patients requiring RVOT reconstruction require multiple sternotomies and cardiac surgical procedures throughout their lives due to the limited lifespan of such conduits (,10 years). Patient management strategies have, therefore, been based on delaying surgical intervention for as long as possible, in order to minimize the number of surgical procedures. However, this approach carries the risk of delaying surgery beyond a point of irreversible right ventricular (RV) dysfunction. A balance between the deleterious effects of RVOT dysfunction and the need to minimize the total number of lifetime surgeries for a given patient is a clinically challenging task prompting the need to develop minimally invasive valve therapies. Since the introduction of PPVI in 2000, the learning curve with this technology lead to significant improvements in both valve design and procedural approach, with several clinical trials demonstrating the safety and efficacy in restoring valvular competence with excellent short to medium term outcomes; transforming this technique from its early pioneering nature into routine clinical care at specialized centers. Evolving data from these studies have shown beneficial effects of PPVI in right ventricular volume reduction, left ventricular filling properties, exercise capacity and electrical remodeling. This review discusses the evolution, indications, and technical aspects of PPVI using the Melody and Edwards SAPIEN transcatheter heart valve as non-surgical treatment options for dysfunctional RVOT/pulmonary trunk.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Coronary embolism after percutaneous implantation of an aortic valve prosthesis.

1. Durán RM, Brotons DA, Argüelles IZ, Concepción PM. Temas de actualidad en cardiología pediátrica y cardiopatías congénitas. Rev Esp Cardiol. 2008;61 Supl 1:15-26. 2. Khambadkone S, Coats L, Taylor A, Boudjemline Y, Derrick G, Tsang V, et al. Percutaneous pulmonary valve implantation in humans: results in 59 consecutive patients. Circulation. 2005;112:1189-97. 3. Lurz P, Coats L, Khambadkone ...

متن کامل

Correlation between RVOT sizing and RV function and volumes in patients with repaired tetralogy of Fallot undergoing routine CMR follow-up: is there a better candidate for percutaneous pulmonary valve implantation?

Background CMR is the established non-invasive tool for routine RV functional and morphological assessment in repaired tetralogy of Fallot (rTOF) patients. 3D anatomical data of the RVOT are routinely performed to better address indications for Pulmonary Valve Replacement (PVR), either surgical or percutaneous. The aim of this crosssectional analysis is to improve the ability of CMR to identify...

متن کامل

Four dimensional pulmonary flow evaluation in adolescent patients after surgical and percutaneous pulmonary valve implantation

Background In patients with congenital heart defects, restoration of the connection between the right ventricle (RV) and the pulmonary artery (PA) by surgical or percutaneous valved conduit implantation is a common procedure. Flow characteristics in such conduits are complex, therefore the aim of this study was demonstrating the potential application of 4D MRI flow for the comprehensive assessm...

متن کامل

The future of transcatheter pulmonary valvulation.

Percutaneous pulmonary valve implantation now has a key role in the setting of dysfunctional right ventricle-to-pulmonary artery conduits or failing bioprosthetic pulmonary valves. However, despite the excellent results obtained with the two devices available currently (the Melody(®) valve [Medtronic Inc., Minneapolis, MN, USA] and the Edwards SAPIEN(®) valve [Edwards Lifesciences, Irvine, CA, ...

متن کامل